Synthesis, characterization, and in vitro study of novel modified reduced graphene oxide (RGO) containing heterocyclic compounds as anti-breast cancer

Nano derivatives of graphene sheets were prepared by functionalized with triazoles. Starting with thiocarbohyderazide which was obtained by refluxing a combination of carbon disulfide and hydrazine hydrate (I), it generated 3-thiol-4-amino-1,2,4-triazole when heated in solid state(II). Anthranilic acid was reacted with (C6H5COCl) to produce 2-phenyl-4H-benzo[d][1,3]oxazin-4-one(III), which was then condensed with the 3-thiol-4-amino-1,2,4-triazol(II) in glacial acetic acid to produce (IV) compound. In addition, the (h2, h3, h4) compounds were used to exfoliate graphite (h1) which contains graphite rods as both anode and cathode, electrolyte, distilled water, sodium bicarbonate, and a power source for the formation of graphene oxide, graphite oxides with a variables acid (h2). Graphene oxide's interaction with hydrazinehydrate yielded (RGO) (h3). The product of (RGO) sonification with thionyl chloride in DMF yielded acyl chloride-functionalized reduced graphene oxide (RGO-COCl) (h4). Compound (IV) was created by reacting (RGO-CO-Cl) with dry THF and Et3N to yield compound (RGO-CO-Cl) (V). Concerning physical features and spectral properties, validity of compounds established by FTIR spectroscopy, and some of them by 1H, 13C-NMR spectrum, XRD, SEM, and AFM. The MCF-7 and VRL-68 cell lines were used to investigate anti-breast cancer and anti-hepatic cancer activity, which could be used as a foundation for the development of novel anticancer medicines.